BillionToOne, Inc. ( BLLN ) shares traded higher premarket on possible continued momentum Tuesday before flattening at the beginning of the session. The company reiterated its fiscal-year 2025 guidance and initiated fiscal-year 2026 financial guidance on Monday.

BillionToOne’s Growth Trajectory Is Unprecedented

BillionToOne ( BLLN ) reiterated full-year 2025 revenue guidance in the range of $293 million to $299 million and said it expects to generate positive GAAP operating income for the year.

The company also introduced full-year 2026 guidance, projecting total revenue of $415 million to $430 million. The outlook represents growth of approximately 40% to 45% compared to the midpoint of the company's 2025 guidance range. BillionToOne ( BLLN ) said it expects to deliver positive GAAP operating income for the full year 2026 as well.

BillionToOne ( BLLN ) said the 2026 outlook reflects its plans to continue scaling its platform through disciplined execution and a focused roadmap aimed at addressing clinical challenges.

BillionToOne Shares Soar During Early Trading

BLLN Price Action: At the time of writing, BillionToOne ( BLLN ) shares are slightly down at 0.14% lower at $99.01, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.